We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Cervical Fluid Test Developed for Gynecological Cancers

By LabMedica International staff writers
Posted on 03 Apr 2018
Print article
Image: Since fluid from the Pap test occasionally contains cells from the endometrium or ovaries, scientists found they could detect cancer cells from these organs that are present in the fluid by using different brushes (Photo courtesy of Johns Hopkins University).
Image: Since fluid from the Pap test occasionally contains cells from the endometrium or ovaries, scientists found they could detect cancer cells from these organs that are present in the fluid by using different brushes (Photo courtesy of Johns Hopkins University).
Together, endometrial and ovarian cancers account for about 25,000 deaths each year and are the third leading cause of cancer-related mortality in women in the USA. Most of these deaths are caused by high-grade tumor subtypes, which tend to metastasize before the onset of symptoms.

Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers. The new screening test called PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and potentially better outcomes for patients.

An international team of scientists working with those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) carried out a retrospective study with samples collected from 1,658 individuals, including 656 patients with endometrial or ovarian cancers and 1,002 healthy controls. The average age of 714 women without cancer who underwent Pap brush analysis was 34 (range, 17 to 67 years). The average age of 125 women without cancer who underwent Tao brush analysis was 29 (range, 18 to 74 years).

For intrauterine sampling, the Tao Brush IUMC Endometrial Sampler was used. For each sample, a single primer pair was used to amplify ~38,000 loci of LINEs throughout the genome. Massively parallel sequencing was performed on Illumina instruments. DNA from Pap brush samples, Tao brush samples, or primary tumors was amplified in three multiplex polymerase chain reactions (PCRs) with 139 primer pairs that were designed to amplify 110- to 142-bp segments. DNA from plasma was amplified in two multiplex PCRs consisting of 61 primer pairs that were designed to amplify 67- to 81-bp segments.

The investigators found that PapSEEK was nearly 99% specific for cancer, and it detected 81% of endometrial cancers and 78% were early-stage cancers and 33% of ovarian cancers and 34% were early-stage cancers. Of the 123 endometrial cancer patients studied using Tao brush samples, PapSEEK identified cancer 93% of the time. Of the 51 ovarian cancer patients studied, 45% tested positive for cancer with PapSEEK. There were no false-positive results. When the plasma and Pap brush samples were both tested, the sensitivity of the test for ovarian cancer increased to 63%.

Lucy Gilbert, M.D. MSc FRCOG, director of gynecologic oncology at McGill University Health Centre, (Montreal, QC, Canada) and a senior author of the study, said, “This allows sampling closer to where the cancers originated. Intrauterine sampling proved particularly important for increasing the detection of ovarian cancer.” The study was published on March 21, 2018, in the journal Science Translational Medicine.

Related Links:
Johns Hopkins University School of Medicine
McGill University Health Centre

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.